Cell-Safe Life sciences

Cell-Safe Life Sciences is pioneering a novel approach to cell therapy with its active implantable immunoisolation device. The Cell-Safe™ system is designed to overcome critical hurdles in cell transplantation, including immune rejection, hypoxia, and the inability to monitor or replenish cells, by providing a self-nourishing, reloadable chamber. Founded in 2017 and based in Boston, the company is in the pre-clinical stage, focusing first on an application for type 1 diabetes. Its technology represents a potential paradigm shift for cell replacement therapies across multiple indications.

The Cell-Safe™ is an active, implantable, immunoisolation device. It is a bioengineered perfusion system that provides a self-nourishing, reloadable chamber for therapeutic cells. It continuously supplies ultrafiltrate to cells to overcome hypoxia, allows for percutaneous reloading and biopsy, and provides immunoprotection without systemic immunosuppression.

Competes with other cell encapsulation companies (e.g., Sernova's Cell Pouch, ViaCyte's PEC-Encapsulation) and developers of alternative diabetes cures (e.g., Vertex's stem cell-derived islets with immunosuppression). Its key differentiators are the active perfusion system for hypoxia mitigation and the reloadable/percutaneous access design.